Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease

Key Inclusion Criteria: -Active Kawasaki disease defined as: * fever ≥38.5°C for ≥5 days * four out of five of the following criteria: (i) conjunctival injection, (ii) oral mucous membrane changes, (e.g., injected pharynx, or strawberry tongue), (iii) erythema of hands or feet, (iv) polymorphous rash, (v) cervical lymphadenopathy Key Exclusion Criteria: Patients fulfilling any of the following criteria are not eligible for inclusion in this study: * Previous Kawasaki Disease diagnosis, refractory and/or incomplete Kawasaki disease (for IVIG-naïve patients, Cohort 1) * Patients who had fever for longer than a week (for Intravenous Immunoglobulin-naïve patients, Cohort 1), or longer than 14 days (for Intravenous Immunoglobulin-refractory patients, Cohort 2) * History of hypersensitivity to any of the study drugs or to drugs or similar chemical classes or excipients (e.g. citric acid and anhydrous sodium chloride disodium edetate dehydrate polysorbate 80; sodium hydroxide; water for injections) Other protocol-defined inclusion/exclusion may apply.